Cardiovascular Drugs Market: By Disease Type (Hypertension, Congestive Heart disease, Angina pectoris, Myocardial Ischemia, Peripheral Artery Diseases, Atherosclerosis, Cardiomyopathy, Others), By Drug Class (Anti-hypertensive Drugs, Lipid lowering drugs, Beta-adrenergic Blocking Agents, Vasodilators, Anti-platelet Agents, Others), By Route of Administration (Oral, Buccal/sublingual, Intravenous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Cardiovascular Drugs Market size was valued at USD 146.51 billion in 2023 and is poised to grow at a significant CAGR of 4.8% from 2024-2030. Cardiovascular drugs are the medications used in the treatment of various cardiovascular diseases. Cardiovascular diseases (CVD) include coronary artery diseases (CAD), myocardial infarction, angina pectoris, hypertension, cardiomyopathy, congenital heart disease, cardiac arrhythmia, peripheral artery diseases, atherosclerosis, and venous thrombosis among others. Majority of the cardiovascular diseases are preventable with cardiovascular drugs, however, in frequent conditions death may occur due to cardiovascular diseases. Global Market has a tremendous growth rate over the forecast years owing to an increase in the prevalence of various cardiovascular diseases and a rise in R&D activities for the innovation of newer drugs.

According to the World Health Organization 2015, approximately 17.7 Mn deaths occurred due to cardiovascular diseases around the world. Moreover, government support to control the diseases, rise in funding from public and private sectors for R&D activities, and patent expiration of blockbusters are bolster the cardiovascular drugs market. Furthermore, acquisitions and mergers, product approvals, and promising pipeline drugs might upsurge the revenue of the cardiovascular drugs market.

Cardiovascular Drugs Market Key Developments:
  • In November 2015, AstraZeneca acquired ZS Pharma to strengthen its cardiovascular drugs portfolio by developing a novel treatment for hyperkalemia, typically associated with chronic heart failure (CHF).
  • In June 2016, Espero Pharmaceuticals received FDA approval for Gonitro (Nitroglycerin) sublingual powder used for acute relief of an angina pectoris attack due to coronary artery disease.

Cardiovascular Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.8%

Largest Market

North America

Fastest Growing Market

Europe
Cardiovascular Drugs Market Dynamics

Increase in the prevalence of cardiovascular diseases, for instance, according to World health organization 2015, approximately 17.7 Mn people died from cardiovascular diseases around the globe, rise in R&D activities for the innovation of newer cardiovascular drugs, government support to increase the awareness about the cardiovascular diseases and treatment are anticipated to fuel the cardiovascular drugs market. Moreover, change in lifestyle, promising product pipeline, rise in prevalence of obesity, and wider access to cardiovascular drugs in the market are anticipated to propel the market. However, stringent regulatory guidelines for the product approval, high cost of treatment, and adverse effects associated with the medications are hampering the growth of cardiovascular drugs market.

Cardiovascular Drugs Market Segmentation

By Indication
  • Hypertension
  • Congestive Heart disease
  • Angina pectoris
  • Myocardial Ischemia
  • Peripheral Artery Diseases
  • Atherosclerosis
  • Cardiomyopathy
  • Others
By Drugs Class
  • Calcium Channel Blockers
  • Angiotensin Converting Enzyme (ACE) inhibitors
  • Angiotensin-II Receptor antagonists
  • Diuretics
  • Lipid-lowering drugs
  • Beta-adrenergic Blocking Agents
  • Vasodilators
  • Anti-platelet Agents
  • Others
By Route of Administration
  • Oral
  • Buccal/sublingual
  • Intravenous
  • Oral
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East Africa

Frequently Asked Questions

The Cardiovascular Drugs Market size was valued at USD 146.51 billion in 2023

The Cardiovascular Drugs Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

The Cardiovascular Drugs Market key players are Capsa Solutions LLC (U.S.), Ergotron, Inc. (Melrose Industries plc) (UK), Enovate Medical (U.S.), Villard (France), Parity Medical (UK), InterMetro Industries Corp. (Emerson Electric) (U.S.), Humanscale Healthcare (U.S.), ITD GmBH (Germany), Compucaddy (U.S.), Advantech Co., Ltd. (China), Bytech Healthcare Ltd. (U.K.)

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  1. Executive Summary
  2. Global Cardiovascular Drugs Market Introduction
    • Global Cardiovascular Drugs Market Taxonomy
    • Global Cardiovascular Drugs Market Definitions
      • Indication
      • Drug Class
      • Route of Administration
      • Distribution Channel
  3. Global Cardiovascular Drugs Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Cardiovascular Drugs Market Dynamic Factors - Impact Analysis
    • Global Cardiovascular Drugs Market Competition Landscape
    • Epidemiology
  4. Global Cardiovascular Drugs Market Analysis, 2019-2023 and Forecast, 2024-2030
    • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  5. Global Cardiovascular Drugs Market, By Indication, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
    • Hypertension
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Congestive Heart disease
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Angina pectoris
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Myocardial Ischemia
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Peripheral Artery Diseases
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Atherosclerosis
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Cardiomyopathy
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis

     6. Global Cardiovascular Drugs Market Forecast, By Drug Class, 2019-2023 and Forecast, 2024-2030

    • Calcium Channel Blockers
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Angiotensin Converting Enzyme (ACE) inhibitors
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Angiotensin-II Receptor antagonists
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Diuretics
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Lipid-lowering drugs
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Beta-adrenergic Blocking Agents
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Vasodilators
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Anti-platelet Agents
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis

    7. Global Cardiovascular Drugs Market Forecast, By Route of Administration, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)

    • Oral
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Buccal/sublingual
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Intravenous
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis

   8. Global Cardiovascular Drugs Market Forecast, By Distribution Channel, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)

    • Hospital Pharmacies
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis

   9. Global Cardiovascular Drugs Market Forecast, By Region, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)

    • North America
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Cardiovascular Drugs Market - Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2018 2024

   10. North America Cardiovascular Drugs MarketAnalysis,2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)

    • Indication Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Hypertension
      • Congestive Heart disease
      • Angina pectoris
      • Myocardial Ischemia
      • Peripheral Artery Diseases
      • Atherosclerosis
      • Cardiomyopathy
      • Others
    • Drug Class Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Calcium Channel Blockers
      • Angiotensin Converting Enzyme (ACE) inhibitors
      • Angiotensin-II Receptor antagonists
      • Diuretics
      • Lipid-lowering drugs
      • Beta-adrenergic Blocking Agents
      • Vasodilators
      • Anti-platelet Agents
      • Others
    • Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Buccal/sublingual
      • Intravenous
      • Others
    • Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2016 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Cardiovascular Drugs Market - Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 2024
    • North America Cardiovascular Drugs Market Dynamics Trends
  1. Europe Cardiovascular Drugs Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
    • Indication Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Hypertension
      • Congestive Heart disease
      • Angina pectoris
      • Myocardial Ischemia
      • Peripheral Artery Diseases
      • Atherosclerosis
      • Cardiomyopathy
      • Others
    • Drug Class Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Calcium Channel Blockers
      • Angiotensin Converting Enzyme (ACE) inhibitors
      • Angiotensin-II Receptor antagonists
      • Diuretics
      • Lipid-lowering drugs
      • Beta-adrenergic Blocking Agents
      • Vasodilators
      • Anti-platelet Agents
      • Others
    • Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Buccal/sublingual
      • Intravenous
      • Others
    • Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Cardiovascular Drugs Market - Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 2024
    • Europe Cardiovascular Drugs Market Dynamics Trends
  2. Asia-Pacific Cardiovascular Drugs Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
    • Indication Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Hypertension
      • Congestive Heart disease
      • Angina pectoris
      • Myocardial Ischemia
      • Peripheral Artery Diseases
      • Atherosclerosis
      • Cardiomyopathy
      • Others
    • Drug Class Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Calcium Channel Blockers
      • Angiotensin Converting Enzyme (ACE) inhibitors
      • Angiotensin-II Receptor antagonists
      • Diuretics
      • Lipid-lowering drugs
      • Beta-adrenergic Blocking Agents
      • Vasodilators
      • Anti-platelet Agents
      • Others
    • Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Buccal/sublingual
      • Intravenous
      • Others
    • Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Cardiovascular Drugs Market - Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 2024
    • Asia-Pacific Cardiovascular Drugs Market Dynamics Trends
  3. Latin America Cardiovascular Drugs Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
    • Indication Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Hypertension
      • Congestive Heart disease
      • Angina pectoris
      • Myocardial Ischemia
      • Peripheral Artery Diseases
      • Atherosclerosis
      • Cardiomyopathy
      • Others
    • Drug Class Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Calcium Channel Blockers
      • Angiotensin Converting Enzyme (ACE) inhibitors
      • Angiotensin-II Receptor antagonists
      • Diuretics
      • Lipid-lowering drugs
      • Beta-adrenergic Blocking Agents
      • Vasodilators
      • Anti-platelet Agents
      • Others
    • Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Buccal/sublingual
      • Intravenous
      • Others
    • Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Cardiovascular Drugs Market - Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 2024
    • Latin America Cardiovascular Drugs Market Dynamics Trends
  4. Middle East and Africa Cardiovascular Drugs Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
    • Indication Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Hypertension
      • Congestive Heart disease
      • Angina pectoris
      • Myocardial Ischemia
      • Peripheral Artery Diseases
      • Atherosclerosis
      • Cardiomyopathy
      • Others
    • Drug Class Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Calcium Channel Blockers
      • Angiotensin Converting Enzyme (ACE) inhibitors
      • Angiotensin-II Receptor antagonists
      • Diuretics
      • Lipid-lowering drugs
      • Beta-adrenergic Blocking Agents
      • Vasodilators
      • Anti-platelet Agents
      • Others
    • Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Buccal/sublingual
      • Intravenous
      • Others
    • Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Cardiovascular Drugs Market - Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 2024
    • MEA Cardiovascular Drugs Market Dynamics Trends
  5. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Indication& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • AstraZeneca plc (U.K.)
      • GlaxoSmithKline plc (U.K.)
      • Novartis AG (Switzerland)
      • Bristol Myers Squibb (U.S.)
      • Pfizer, Inc. (U.S.)
      • Sanofi S.A. (France)
      • Boehringer Ingelheim GmbH (Germany)
      • Johnson & Johnson Services, Inc. (U.S.)
      • Bayer AG (Germany)
      • Merck & Co., Inc. (U.S.)
      • Espero Pharmaceuticals, Inc. (U.S.)

   16. Research Methodology

  1. Key Assumptions and Acronyms
  • Capsa Solutions LLC (U.S.)
  • Ergotron, Inc. (Melrose Industries plc) (UK)
  • Enovate Medical (U.S.)
  • Villard (France)
  • Parity Medical (UK)
  • InterMetro Industries Corp. (Emerson Electric) (U.S.)
  • Humanscale Healthcare (U.S.)
  • ITD GmBH (Germany)
  • Compucaddy (U.S.)
  • Advantech Co., Ltd. (China)
  • Bytech Healthcare Ltd. (U.K.)

Adjacent Markets